The DOI matches its Crossref record; 302 of the 302 references it cites were found in a registry or an index.
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
Open accessAbstract
Recently, immune checkpoint inhibitors (ICIs) therapy has become a promising therapeutic strategy with encouraging therapeutic outcomes due to their durable anti-tumor effects. Though, tumor inherent or acquired resistance to ICIs accompanied with treatment-related toxicities hamper their clinical utility. Overall, about 60–70% of patients (e.g., melanoma and lung cancer) who received ICIs show no objective response to intervention. The resistance to ICIs mainly caused by alterations in the tumor microenvironment (TME), which in turn, supports angiogenesis and also blocks immune cell antitumor activities, facilitating tumor cells' evasion from host immunosurveillance. Thereby, it has been supposed and also validated that combination therapy with ICIs and other therapeutic means, ranging from chemoradiotherapy to targeted therapies as well as cancer vaccines, can capably compromise tumor resistance to immune checkpoint blocked therapy. Herein, we have focused on the therapeutic benefits of ICIs as a groundbreaking approach in the context of tumor immunotherapy and also deliver an overview concerning the therapeutic influences of the addition of ICIs to other modalities to circumvent tumor resistance to ICIs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357 · cited 3×
“Thereby, combination therapy showed superiority over monotherapy with ipilimumab or nivolumab in terms of efficacy, while a higher rate of the occurrences of irAEs dampens its clinical use [76].”
BackgroundInfluentialFreeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 1×
“On the other hand, the PD-1 functions as a critical immune checkpoint were documented upon detecting its central ligand, PD-L1, which is found on multiple cell types such as tumor cells, immune cells, epithelial cells, and endothelial cells [11].”
BackgroundNivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656 · cited 10×
“As well, there is clear evidence presenting that addition of the nivolumab to sunitinib or pazopanib could be an effective alternative for the treatment of advanced RCC patients [34, 178].”
MethodInfluentialAtezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830 · cited 1×
“As evidenced in melanoma, it appears that β-catenin activation could suppress the expression of chemokine chemokine (C–C motif ) ligands 4 (CCL4), which is mainly complicated in immune cell infiltration into TME [130, 131].”
BackgroundNivolumab plus ipilimumab in advanced non-small-cell lung cancer
Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910231 · Cited by 2,823
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
Paz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32222-6 · Cited by 2,298 · cited 3×
“These approvals were rendering consequences derived from two randomized controlled trials, IMpower133 (atezolizumab) [137] and CASPIAN (durvalumab) [109].”
BackgroundMethodCTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112824 · Cited by 2,087
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Immune checkpoint inhibitors: recent progress and potential biomarkers
Darvin, P., Toor, S. M., Sasidharan Nair, V., & Elkord, E. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0191-1 · Cited by 2,035
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Choueiri, T. K., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Zurawski, B., Oyervides Juárez, V. M., Hsieh, J. J., Basso, U., Shah, A. Y., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2026982 · Cited by 1,791
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
West, H., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H. J., Kopp, H.-G., Daniel, D., McCune, S., Mekhail, T., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30167-6 · Cited by 1,662
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Powles, T., Park, S. H., Voog, E., Caserta, C., Valderrama, B. P., Gurney, H., Kalofonos, H., Radulović, S., Demey, W., Ullén, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002788 · Cited by 1,493
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472 · cited 17×
“ICI immune checkpoint inhibitor, PD-1 programmed cell death protein 1, PD-L1 programmed death-ligand 1, CTLA-4 cytotoxic-T-lymphocyte-associated protein 4, CTLs cytotoxic T cells, IFN interferon, Tregs regulatory T cells, TME tumor microenvironment, TILs tumor-infiltrating lymphocytes, APC antigen-presenting cell, MDS…”
BackgroundInfluentialAnti–PD-1/PD-L1 therapy of human cancer: past, present, and future
Chen, L., & Han, X. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80011 · Cited by 1,437
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
Migden, M. R., Rischin, D., Schmults, C. D., Guminski, A., Hauschild, A., Lewis, K. D., Chung, C. H., Hernandez-Aya, L., Lim, A. M., Chang, A. L. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805131 · Cited by 1,411
Mechanisms of resistance to immune checkpoint inhibitors
Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383 · cited 2×
“Recent reports have shown that objective response rate (ORR) in melanoma patients treated with PD-1 inhibitors is only 33%, and also more than 70% of non-small-cell lung carcinoma (NSCLC) patients exhibit no response to ICIs [21].”
BackgroundPaz-Ares, L., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30641-0 · Cited by 1,366
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337
Yau, T., Kang, Y.-K., Kim, T.-Y., El-Khoueiry, A. B., Santoro, A., Sangro, B., Melero, I., Kudo, M., Hou, M.-M., Matilla, A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4564 · Cited by 1,273
McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0053-3 · Cited by 1,260
Shaverdian, N., Lisberg, A. E., Bornazyan, K., Veruttipong, D., Goldman, J. W., Formenti, S. C., Garon, E. B., & Lee, P. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30380-7 · Cited by 1,091 · cited 2×
“Thereby, it was simplified that application of ICIs along with RT may be considered as an effective strategy in patients with NSCLC or even other tumors [91].”
Backgroundvan Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020 · cited 1×
“Similarly, combined use of GMCSF cell-based vaccines (GVAX) and CTLA-4 inhibitor decreased tumor size and restored the antitumor immune responses in melanoma [29], prostate [186], and also PDA [187] murine model.”
BackgroundAttia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Lynch, T. J., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Neal, J., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 1,002
Acquired Resistance to Immune Checkpoint Inhibitors
Schoenfeld, A. J., & Hellmann, M. D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.017 · Cited by 955
Voorwerk, L., Slagter, M., Horlings, H. M., Sikorska, K., van de Vijver, K. K., de Maaker, M., Nederlof, I., Kluin, R. J. C., Warren, S., Ong, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0432-4 · Cited by 905
Fukuoka, S., Hara, H., Takahashi, N., Kojima, T., Kawazoe, A., Asayama, M., Yoshii, T., Kotani, D., Tamura, H., Mikamoto, Y., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03296 · Cited by 890 · cited 11×
“The safety and efficacy of combination therapy with nivolumab plus ipilimumab also was indicated in dMMR/ MSI-H metastatic CRC [70].”
BackgroundInfluentialPowles, T., O'Donnell, P. H., Massard, C., Arkenau, H.-T., Friedlander, T. W., Hoimes, C. J., Lee, J. L., Ong, M., Sridhar, S. S., Vogelzang, N. J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2411 · Cited by 869 · cited 2×
“Durvalumab administration (10 mg/kg) could provoke improved ORR, OS, and PFS concomitant with the excellent safety profile in patients with UC (NCT01693562) [115].”
BackgroundHorn, L., Spigel, D. R., Vokes, E. E., Holgado, E., Ready, N., Steins, M., Poddubskaya, E., Borghaei, H., Felip, E., Paz-Ares, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.3062 · Cited by 861
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Rafiq, S., Yeku, O. O., Jackson, H. J., Purdon, T. J., van Leeuwen, D. G., Drakes, D. J., Song, M., Miele, M. M., Li, Z., Wang, P., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4195 · Cited by 833
CTLA-4 ligation blocks CD28-dependent T cell activation.
Walunas, T. L., Bakker, C. Y., & Bluestone, J. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.6.2541 · Cited by 801
Sezer, A., Kilickap, S., Gümüş, M., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., Turk, H. M., Cicin, I., Bentsion, D., Gladkov, O., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00228-2 · Cited by 789
Galsky, M. D., Arija, J. Á. A., Bamias, A., Davis, I. D., De Santis, M., Kikuchi, E., Garcia-del-Muro, X., De Giorgi, U., Mencinger, M., Izumi, K., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30230-0 · Cited by 786
CD28-mediated co-stimulation: a quantitative support for TCR signalling.
Acuto, O., & Michel, F. (2003) · Nature Reviews Immunology · doi:10.1038/nri1248 · Cited by 775
Wallin, J. J., Bendell, J. C., Funke, R., Sznol, M., Korski, K., Jones, S., Hernandez, G., Mier, J., He, X., Hodi, F. S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12624 · Cited by 713
Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies.
Byun, D. J., Wolchok, J. D., Rosenberg, L. M., & Girotra, M. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.205 · Cited by 685 · cited 1×
“Among the checkpoint-blocking strategies, inhibition of the cytotoxic-T-lymphocyte-associated protein 4 (CTLA-4 or CD152) and also blocking the interfaces between programmed cell death 1 (PD-1 or CD279) and programmed cell death ligand 1 (PD-L1 or CD274 or B7 homolog 1) has gained increasing attention [5].”
BackgroundMolecular Basis of T Cell Inactivation by CTLA-4
Lee, K.-M., Chuang, E., Griffin, M., Khattri, R., Hong, D. K., Zhang, W., Straus, D., Samelson, L. E., Thompson, C. B., & Bluestone, J. A. (1998) · Science · doi:10.1126/science.282.5397.2263 · Cited by 684
Gutzmer, R., Stroyakovskiy, D., Gogas, H., Robert, C., Lewis, K., Protsenko, S., Pereira, R. P., Eigentler, T., Rutkowski, P., Demidov, L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30934-x · Cited by 663
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Twomey, J. D., & Zhang, B. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00574-0 · Cited by 657
Fares, C. M., Van Allen, E. M., Drake, C. G., Allison, J. P., & Hu-Lieskovan, S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_240837 · Cited by 653
Cancer vaccines: between the idea and the reality
Finn, O. J. (2003) · Nature Reviews Immunology · doi:10.1038/nri1150 · Cited by 636
Chesney, J., Puzanov, I., Collichio, F., Singh, P., Milhem, M. M., Glaspy, J., Hamid, O., Ross, M., Friedlander, P., Garbe, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7379 · Cited by 631
Adusumilli, P. S., Zauderer, M. G., Rivière, I., Solomon, S. B., Rusch, V. W., O'Cearbhaill, R. E., Zhu, A., Cheema, W., Chintala, N. K., Halton, E., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0407 · Cited by 605
Bevacizumab plus ipilimumab in patients with metastatic melanoma
Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T., Zeng, W., Giobbie-Hurder, A., Atkins, M. B., Ibrahim, N., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0053 · Cited by 593
Saha, D., Martuza, R. L., & Rabkin, S. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.006 · Cited by 591
Le, D. T., Lutz, E., Uram, J. N., Sugar, E. A., Onners, B., Solt, S., Zheng, L., Diaz, L. A., Donehower, R. C., Jaffee, E. M., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31829fb7a2 · Cited by 564
Advances in cancer immunotherapy 2019 – latest trends
Kruger, S., Ilmer, M., Kobold, S., Cadilha, B. L., Endres, S., Ormanns, S., Schuebbe, G., Renz, B. W., D’Haese, J. G., Schloesser, H., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1266-0 · Cited by 563
Puzanov, I., Milhem, M. M., Minor, D., Hamid, O., Li, A., Chen, L., Chastain, M., Gorski, K. S., Anderson, A., Chou, J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1529 · Cited by 562
Sunshine, J., & Taube, J. M. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.05.011 · Cited by 560
Slovin, S. F., Higano, C. S., Hamid, O., Tejwani, S., Harzstark, A., Alumkal, J. J., Scher, H. I., Chin, K., Gagnier, P., McHenry, M. B., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt107 · Cited by 559
Socinski, M. A., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.009 · Cited by 529
Motzer, R. J., Robbins, P. B., Powles, T., Albiges, L., Haanen, J. B., Larkin, J., Mu, X. J., Ching, K. A., Uemura, M., Pal, S. K., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1044-8 · Cited by 518
Rubin, I., & Yarden, Y. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_1.s3 · Cited by 500
Migden, M. R., Khushalani, N. I., Chang, A. L. S., Lewis, K. D., Schmults, C. D., Hernandez-Aya, L., Meier, F., Schadendorf, D., Guminski, A., Hauschild, A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30728-4 · Cited by 496
Massarelli, E., William, W., Johnson, F., Kies, M., Ferrarotto, R., Guo, M., Feng, L., Lee, J. J., Tran, H., Kim, Y. U., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4051 · Cited by 490
Scherpereel, A., Mazieres, J., Greillier, L., Lantuejoul, S., Dô, P., Bylicki, O., Monnet, I., Corre, R., Audigier-Valette, C., Locatelli-Sanchez, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30765-4 · Cited by 454
Chen, Y., Ramjiawan, R. R., Reiberger, T., Ng, M. R., Hato, T., Huang, Y., Ochiai, H., Kitahara, S., Unan, E. C., Reddy, T. P., et al. (2015) · Hepatology · doi:10.1002/hep.27665 · Cited by 451
Taylor, M. H., Lee, C.-H., Makker, V., Rasco, D., Dutcus, C. E., Wu, J., Stepan, D. E., Shumaker, R. C., & Motzer, R. J. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01598 · Cited by 435
Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo
Read, S., Greenwald, R., Izcue, A., Robinson, N., Mandelbrot, D., Francisco, L., Sharpe, A. H., & Powrie, F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4376 · Cited by 434 · cited 1×
“as well as anti-tumor activities of tumor-infiltrating lymphocytes (TILs), in particular, cytotoxic T lymphocytes (CTL) [10].”
BackgroundCTLA-4 regulates induction of anergy in vivo
Greenwald, R. J., Boussiotis, V. A., Lorsbach, R. B., Abbas, A. K., & Sharpe, A. H. (2001) · Immunity · doi:10.1016/s1074-7613(01)00097-8 · Cited by 428 · cited 2×
“The evidence regarding the CTLA-4 activities offered the concept that dampening its activities could enable durable T cell responses [7].”
BackgroundPardoll, D. M. (1998) · Nature Medicine · doi:10.1038/nm0598supp-525 · Cited by 428
Hurwitz, A. A., Foster, B. A., Kwon, E. D., Truong, T. N., Choi, E. M., Greenberg, N. M., Burg, M. B., & Allison, J. P. (2000) · PubMed · Cited by 425
Co-stimulation in T cell responses
Chambers, C. A., & Allison, J. P. (1997) · Current Opinion in Immunology · doi:10.1016/s0952-7915(97)80087-8 · Cited by 415
Small, E. J., Tchekmedyian, N. S., Rini, B. I., Fong, L., Lowy, I., & Allison, J. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2318 · Cited by 407
Soares, K. C., Rucki, A. A., Wu, A. A., Olino, K., Xiao, Q., Chai, Y., Wamwea, A., Bigelow, E., Lutz, E., Liu, L., et al. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000062 · Cited by 398
Wilky, B. A., Trucco, M. M., Subhawong, T. K., Florou, V., Park, W., Kwon, D., Wieder, E. D., Kolonias, D., Rosenberg, A. E., Kerr, D. A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30153-6 · Cited by 392
Samson, A., Scott, K. J., Taggart, D., West, E. J., Wilson, E., Nuovo, G. J., Thomson, S., Corns, R., Mathew, R. K., Fuller, M. J., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aam7577 · Cited by 373
Atkins, M. B., Plimack, E. R., Puzanov, I., Fishman, M. N., McDermott, D. F., Cho, D. C., Vaishampayan, U., George, S., Olencki, T. E., Tarazi, J. C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30081-0 · Cited by 370
Müller, P., Kreuzaler, M., Khan, T., Thommen, D. S., Martin, K., Glatz, K., Savic, S., Harbeck, N., Nitz, U., Gluz, O., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4925 · Cited by 349
Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer
Meric-Bernstam, F., Johnson, A. M., Dumbrava, E. E. I., Raghav, K., Balaji, K., Bhatt, M., Murthy, R. K., Rodon, J., & Piha-Paul, S. A. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2275 · Cited by 349
Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
Philips, G. K., & Atkins, M. (2015) · International Immunology · doi:10.1093/intimm/dxu095 · Cited by 335
Kaufman, H. L., Russell, J. S., Hamid, O., Bhatia, S., Terheyden, P., D’Angelo, S. P., Shih, K. C., Lebbé, C., Milella, M., Brownell, I., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0310-x · Cited by 334
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
Chen, R., Zinzani, P. L., Lee, H. J., Armand, P., Johnson, N. A., Brice, P., Radford, J., Ribrag, V., Molin, D., Vassilakopoulos, T. P., et al. (2019) · Blood · doi:10.1182/blood.2019000324 · Cited by 331
Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis
Kryczek, I., Wei, S., Keller, E., Liu, R., & Zou, W. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00406.2006 · Cited by 329
Ueno, M., Ikeda, M., Morizane, C., Kobayashi, S., Ohno, I., Kondo, S., Okano, N., Kimura, K., Asada, S., Namba, Y., et al. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30086-x · Cited by 328
Madan, R. A., Mohebtash, M., Arlen, P. M., Vergati, M., Rauckhorst, M., Steinberg, S. M., Tsang, K. Y., Poole, D. J., Parnes, H. L., Wright, J. J., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70006-2 · Cited by 326
Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion
Jiang, Y., & Zhan, H. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.10.013 · Cited by 319
Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
Ferrucci, P. F., Pala, L., Conforti, F., & Cocorocchio, E. (2021) · Cancers · doi:10.3390/cancers13061383 · Cited by 317
Kythreotou, A., Siddique, A., Mauri, F. A., Bower, M., & Pinato, D. J. (2018) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2017-204853 · Cited by 317
Zhang, X., Zeng, Y., Qu, Q., Zhu, J., Liu, Z., Ning, W., Zeng, H., Zhang, N., Du, W., Chen, C., et al. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1161-7 · Cited by 316
Immunotherapy and tumor microenvironment
Tang, H., Qiao, J., & Fu, Y.-X. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.10.009 · Cited by 308
Pai-Scherf, L., Blumenthal, G. M., Li, H., Subramaniam, S., Mishra-Kalyani, P. S., He, K., Zhao, H., Yu, J., Paciga, M., Goldberg, K. B., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0078 · Cited by 294
WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment
Li, X., Xiang, Y., Li, F., Yin, C., Li, B., & Ke, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02293 · Cited by 291
Iwata, T. N., Ishii, C., Ishida, S., Ogitani, Y., Wada, T., & Agatsuma, T. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0749 · Cited by 291
Resistance to Checkpoint Inhibition in Cancer Immunotherapy
Barrueto, L., Caminero, F., Cash, L., Makris, C., Lamichhane, P., & Deshmukh, R. R. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.12.010 · Cited by 281
Zhang, L., Zlotoff, D. A., Awadalla, M., Mahmood, S. S., Nohria, A., Hassan, M. Z. O., Thuny, F., Zubiri, L., Chen, C. L., Sullivan, R. J., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044703 · Cited by 281
CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy
Engeland, C. E., Grossardt, C., Veinalde, R., Bossow, S., Lutz, D., Kaufmann, J. K., Shevchenko, I., Umansky, V., Nettelbeck, D. M., Weichert, W., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.160 · Cited by 280
Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
Zhou, W., Guo, S., Liu, M., Burow, M. E., & Wang, G. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867324666170830111531 · Cited by 278
Grabosch, S., Bulatovic, M., Zeng, F., Ma, T., Zhang, L., Ross, M., Brozick, J., Fang, Y., Tseng, G., Kim, E., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0581-9 · Cited by 278
Choueiri, T. K., Larkin, J., Oya, M., Thistlethwaite, F., Martignoni, M., Nathan, P., Powles, T., McDermott, D., Robbins, P. B., Chism, D. D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30107-4 · Cited by 260 · cited 10×
“As well, there is clear evidence presenting that addition of the nivolumab to sunitinib or pazopanib could be an effective alternative for the treatment of advanced RCC patients [34, 178].”
BackgroundInfluentialThe pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis
Wang, J., Loberg, R., & Taichman, R. S. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9019-x · Cited by 256
CXCR4/CXCL12 expression and signalling in kidney cancer
Schrader, A. J., Lechner, O., Templin, M., Dittmar, K. E. J., Machtens, S., Mengel, M., Probst-Kepper, M., Franzke, A., Wollensak, T., Gatzlaff, P., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600221 · Cited by 254
Fournel, L., Wu, Z., Stadler, N., Damotte, D., Lococo, F., Boulle, G., Ségal-Bendirdjian, E., Bobbio, A., Icard, P., Trédaniel, J., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.08.005 · Cited by 249
A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy
Hiniker, S. M., Chen, D. S., Reddy, S., Chang, D. T., Jones, J. C., Mollick, J. A., Swetter, S. M., & Knox, S. J. (2012) · Translational Oncology · doi:10.1593/tlo.12280 · Cited by 247
Hudson, K., Cross, N., Jordan-Mahy, N., & Leyland, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.568931 · Cited by 243
Immune checkpoints in the tumor microenvironment
Toor, S. M., Sasidharan Nair, V., Decock, J., & Elkord, E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.021 · Cited by 236
Predicting benefit from anti-angiogenic agents in malignancy
Jubb, A. M., Oates, A. J., Holden, S., & Koeppen, H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1946 · Cited by 228
Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC
Chu, T., Zhong, R., Zhong, H., Zhang, B., Zhang, W., Shi, C., Qian, J., Zhang, Y., Chang, Q., Zhang, X., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.026 · Cited by 227
Seo, Y. D., Jiang, X., Sullivan, K. M., Jalikis, F. G., Smythe, K. S., Abbasi, A., Vignali, M., Park, J. O., Daniel, S. K., Pollack, S. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0081 · Cited by 227
Larkin, J., Lao, C. D., Urba, W. J., McDermott, D. F., Horak, C., Jiang, J., & Wolchok, J. D. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1184 · Cited by 223
Liu, J. F., Herold, C., Gray, K. P., Penson, R. T., Horowitz, N., Konstantinopoulos, P. A., Castro, C. M., Hill, S. J., Curtis, J., Luo, W., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3343 · Cited by 222
Trends in clinical development for PD-1/PD-L1 inhibitors
Xin Yu, J., Hodge, J. P., Oliva, C., Neftelinov, S. T., Hubbard-Lucey, V. M., & Tang, J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-019-00182-w · Cited by 222
Lampert, E. J., Zimmer, A., Padget, M., Cimino-Mathews, A., Nair, J. R., Liu, Y., Swisher, E. M., Hodge, J. W., Nixon, A. B., Nichols, E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0056 · Cited by 220
Rosewell Shaw, A., Porter, C. E., Watanabe, N., Tanoue, K., Sikora, A., Gottschalk, S., Brenner, M. K., & Suzuki, M. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.010 · Cited by 219
Feros, D. L., Lane, L., Ciarrochi, J., & Blackledge, J. T. (2013) · Psycho-Oncology · doi:10.1002/pon.2083 · Cited by 216 · cited 1×
“ICIs with ACT Adoptive cell therapy (ACT) with using TILs or genemodified T cells expressing novel T cell receptors (TCR) or chimeric antigen receptors (CAR) is another tactic to inspire the immune system to induce and so detect maligned cells and eradicate them [215, 216].”
BackgroundFeng, B., Niu, Z., Hou, B., Zhou, L., Li, Y., & Yu, H. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201906605 · Cited by 215
D'Angelo, S. P., Bhatia, S., Brohl, A. S., Hamid, O., Mehnert, J. M., Terheyden, P., Shih, K. C., Brownell, I., Lebbé, C., Lewis, K. D., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000674 · Cited by 203
Al-Abd, A. M., Alamoudi, A. J., Abdel-Naim, A. B., Neamatallah, T. A., & Ashour, O. M. (2017) · Journal of Advanced Research · doi:10.1016/j.jare.2017.06.006 · Cited by 198
Jiang, H., Rivera-Molina, Y., Gomez-Manzano, C., Clise-Dwyer, K., Bover, L., Vence, L. M., Yuan, Y., Lang, F. F., Toniatti, C., Hossain, M. B., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0468 · Cited by 197
Brix, N., Tiefenthaller, A., Anders, H., Belka, C., & Lauber, K. (2017) · Immunological Reviews · doi:10.1111/imr.12573 · Cited by 197
Yang, P., Song, H., Qin, Y., Huang, P., Zhang, C., Kong, D., & Wang, W. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b01406 · Cited by 197
Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study
Kamath, S. D., Kalyan, A., Kircher, S., Nimeiri, H., Fought, A. J., Benson, A., & Mulcahy, M. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0473 · Cited by 194
Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer: An Update
Guallar-Garrido, S., & Julián, E. (2020) · ImmunoTargets and Therapy · doi:10.2147/itt.s202006 · Cited by 194
Sugawara, S., Lee, J.-S., Kang, J.-H., Kim, H. R., Inui, N., Hida, T., Lee, K. H., Yoshida, T., Tanaka, H., Yang, C.-T., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.004 · Cited by 193
Zeng, Y., Li, B., Liang, Y., Reeves, P. M., Qu, X., Ran, C., Liu, Q., Callahan, M. V., Sluder, A. E., Gelfand, J. A., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201802067rr · Cited by 191
CD28 co-stimulation in T-cell homeostasis: a recent perspective
Hünig, T., Beyersdorf, N., & Kerkau, T. (2015) · ImmunoTargets and Therapy · doi:10.2147/itt.s61647 · Cited by 190
Catenacci, D. V. T., Kang, Y.-K., Park, H., Uronis, H. E., Lee, K.-W., Ng, M. C. H., Enzinger, P. C., Park, S. H., Gold, P. J., Lacy, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30326-0 · Cited by 190
Woller, N., Gürlevik, E., Fleischmann-Mundt, B., Schumacher, A., Knocke, S., Kloos, A. M., Saborowski, M., Geffers, R., Manns, M. P., Wirth, T. C., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.115 · Cited by 186
Mazieres, J., Rittmeyer, A., Gadgeel, S., Hida, T., Gandara, D. R., Cortinovis, D. L., Barlesi, F., Yu, W., Matheny, C., Ballinger, M., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.09.022 · Cited by 185
Anassi, E., & Ndefo, U. A. (2011) · PubMed Central · Cited by 184
Martin-Broto, J., Hindi, N., Grignani, G., Martinez-Trufero, J., Redondo, A., Valverde, C., Stacchiotti, S., Lopez-Pousa, A., D'Ambrosio, L., Gutierrez, A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001561 · Cited by 183
Pike, L. R. G., Bang, A., Mahal, B. A., Taylor, A., Krishnan, M., Spektor, A., Cagney, D. N., Aizer, A. A., Alexander, B. M., Rahma, O., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.09.010 · Cited by 183
Rajani, K., Parrish, C., Kottke, T., Thompson, J., Zaidi, S., Ilett, L., Shim, K. G., Diaz, R.-M., Pandha, H., Harrington, K., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2015.156 · Cited by 182
Casak, S. J., Donoghue, M., Fashoyin-Aje, L., Jiang, X., Rodriguez, L., Shen, Y.-L., Xu, Y., Jiang, X., Liu, J., Zhao, H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3407 · Cited by 181
Amin, A., Plimack, E. R., Ernstoff, M. S., Lewis, L. D., Bauer, T. M., McDermott, D. F., Carducci, M., Kollmannsberger, C., Rini, B. I., Heng, D. Y. C., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0420-0 · Cited by 180
Rischin, D., Migden, M. R., Lim, A. M., Schmults, C. D., Khushalani, N. I., Hughes, B. G. M., Schadendorf, D., Dunn, L. A., Hernandez-Aya, L., Chang, A. L. S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000775 · Cited by 177
Wolchok, J. D., Weber, J. S., Maio, M., Neyns, B., Harmankaya, K., Chin, K., Cykowski, L., de Pril, V., Humphrey, R., & Lebbé, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt161 · Cited by 176
Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds
Sivanandam, V., LaRocca, C. J., Chen, N. G., Fong, Y., & Warner, S. G. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.04.003 · Cited by 176
The immune mechanisms of abscopal effect in radiation therapy
Grass, G. D., Krishna, N., & Kim, S. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2015.10.003 · Cited by 175
Tsujikawa, T., Crocenzi, T. S., Durham, J. N., Sugar, E. A., Wu, A. A., Onners, B., Nauroth, J. M., Anders, R. A., Fertig, E. J., Laheru, D. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3978 · Cited by 172
Li, Z., Wang, Y., Shen, Y., Qian, C., Oupicky, D., & Sun, M. (2020) · Science Advances · doi:10.1126/sciadv.aaz9240 · Cited by 171
PD-1 blockade enhances the vaccination-induced immune response in glioma
Antonios, J. P., Soto, H., Everson, R. G., Orpilla, J., Moughon, D., Shin, N., Sedighim, S., Yong, W. H., Li, G., Cloughesy, T. F., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87059 · Cited by 170
Durvalumab: First Global Approval
Syed, Y. Y. (2017) · Drugs · doi:10.1007/s40265-017-0782-5 · Cited by 170
Interaction of SHP‐2 SH2 domains with PD‐1 ITSM induces PD‐1 dimerization and SHP‐2 activation
Patsoukis, N., Duke-Cohan, J. S., Chaudhri, A., Aksoylar, H.-I., Wang, Q., Council, A., Berg, A., Freeman, G. J., & Boussiotis, V. A. (2020) · Communications Biology · doi:10.1038/s42003-020-0845-0 · Cited by 169
CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy
Brunner-Weinzierl, M. C., & Rudd, C. E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02737 · Cited by 169
De Keersmaecker, B., Claerhout, S., Carrasco, J., Bar, I., Corthals, J., Wilgenhof, S., Neyns, B., & Thielemans, K. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000329 · Cited by 165
Chen, J., Feng, Y., Lu, L., Wang, H., Dai, L., Li, Y., & Zhang, P. (2012) · Immunobiology · doi:10.1016/j.imbio.2011.10.016 · Cited by 164
Abscopal effect in radioimmunotherapy
Ashrafizadeh, M., Farhood, B., Musa, A. E., Taeb, S., Rezaeyan, A., & Najafi, M. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106663 · Cited by 164
Erfani, N., Mehrabadi, S. M., Ghayumi, S. M. A., Haghshenas, M. R., Mojtahedi, Z., Ghaderi, A. A., & Amani, D. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.04.011 · Cited by 163
Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade
Li, Q., Wang, Y., Jia, W., Deng, H., Li, G., Deng, W., Chen, J., Kim, B. Y. S., Jiang, W., Liu, Q., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2179 · Cited by 163
Immune checkpoint inhibitor toxicities
Marin-Acevedo, J. A., Chirila, R. M., & Dronca, R. S. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.03.012 · Cited by 160
Bang, A., Wilhite, T. J., Pike, L. R. G., Cagney, D. N., Aizer, A. A., Taylor, A., Spektor, A., Krishnan, M., Ott, P. A., Balboni, T. A., et al. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.02.003 · Cited by 159
Derer, A., Frey, B., Fietkau, R., & Gaipl, U. S. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1771-8 · Cited by 158
Sondak, V. K., Smalley, K. S. M., Kudchadkar, R. R., Grippon, S., & Kirkpatrick, P. N. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3463 · Cited by 158
Hou, A., Hou, K., Huang, Q., Lei, Y., & Chen, W.-L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00783 · Cited by 155
Ali, O. A., Lewin, S. A., Dranoff, G., & Mooney, D. J. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0126 · Cited by 151
Mathieu, L. N., Shah, S., Pai-Scherf, L. H., Larkins, E. A., Vallejo, J. J., Li, X., Rodríguez, L., Mishra-Kalyani, P. S., Goldberg, K. B., Kluetz, P. G., et al. (2021) · The Oncologist · doi:10.1002/onco.13752 · Cited by 149
Grasselly, C., Denis, M., Bourguignon, A., Talhi, N., Mathé, D., Tourette, A., Serre, L., Jordheim, L. P., Matera, E. L., & Dumontet, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02100 · Cited by 144
Wu, A., Maxwell, R., Xia, Y., Cardarelli, P. M., Oyasu, M., Belcaid, Z., Kim, E. S., Hung, A. L., Luksik, A. S., Garzón-Muvdi, T., et al. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03172-5 · Cited by 142
Hardcastle, J. J., Mills, L., Malo, C. S., Jin, F., Kurokawa, C., Geekiyanage, H., Schroeder, M. A., Sarkaria, J. N., Johnson, A. J., & Galanis, E. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now179 · Cited by 141
D’Amico, L., Menzel, U., Prummer, M., Müller, P., Buchi, M., Kashyap, A. S., Haessler, U., Yermanos, A., Gébleux, R., Briendl, M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0464-1 · Cited by 140
Rischin, D., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A. K., Basté, N., Neupane, P. C., Bratland, Å., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.6000 · Cited by 138
Lévy, A., Massard, C., Soria, J., & Deutsch, É. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.09.013 · Cited by 135
Salvi, S., Fontana, V., Boccardo, S., Merlo, D. F., Margallo, E., Laurent, S., Morabito, A., Rijavec, E., Dal Bello, M. G., Mora, M., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1211-y · Cited by 133
Fu, J. L., Malm, I., Kadayakkara, D. K. K., Levitsky, H., Pardoll, D. M., & Kim, Y. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2685 · Cited by 133
Du, W., Seah, I. Y. J., Bougazzoul, O., Choi, G., Meeth, K. M., Bosenberg, M., Wakimoto, H., Fisher, D. E., & Shah, K. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700363114 · Cited by 129
Sen, T., Corte, C. M. D., Milutinovic, S., Cardnell, R. J., Diao, L., Ramkumar, K., Gay, C. M., Stewart, C. A., Fan, Y.-H., Shen, L., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.08.009 · Cited by 123
D’Alterio, C., Buoncervello, M., Ieranò, C., Napolitano, M., Portella, L., Rea, G., Barbieri, A., Luciano, A., Scognamiglio, G., Tatangelo, F., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1420-8 · Cited by 122
Feng, K., Liu, Y., Zhao, Y., Yang, Q., Dong, L., Liu, J., Li, X., Zhao, Z., Mei, Q., & Han, W. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000367 · Cited by 120
Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations
Gatti-Mays, M. E., Redman, J. M., Collins, J. M., & Bilušić, M. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1364322 · Cited by 119
Vermeulen, J. F., Hecke, W. V., Adriaansen, E. J. M., Jansen, M. K., Bouma, R. G., Hidalgo, J. V., Fisch, P., Broekhuizen, R., Spliet, W. G. M., Kool, M., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1398877 · Cited by 119
Ho, T. T. B., Nasti, A., Seki, A., Komura, T., Inui, H., Kozaka, T., Kitamura, Y., Shiba, K., Yamashita, T., Yamashita, T., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001367 · Cited by 119
Johnson, D. B., Reynolds, K. L., Sullivan, R. J., Balko, J. M., Patrinely, J. R., Cappelli, L. C., Naidoo, J., & Moslehi, J. J. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30107-8 · Cited by 118
Zimmer, A. S., Nichols, E. H., Cimino‐Mathews, A., Peer, C. J., Cao, L., Lee, M.-J., Kohn, E. C., Annunziata, C. M., Lipkowitz, S., Trepel, J. B., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0680-3 · Cited by 118
CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer
Bengsch, F., Knoblock, D. M., Liu, A., McAllister, F. M., & Beatty, G. L. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2053-4 · Cited by 114
Morse, M. A., Overman, M. J., Hartman, L., Khoukaz, T., Brutcher, E., Lenz, H.-J., Atasoy, A., Shangguan, T., Zhao, H., & El-Rayes, B. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0129 · Cited by 112
Singh, M., Vianden, C., Cantwell, M. J., Dai, Z., Xiao, Z., Sharma, M., Khong, H., Jaiswal, A. R., Fa’ak, F., Hailemichael, Y., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01572-7 · Cited by 112
Kudo, M., Motomura, K., Wada, Y., Inaba, Y., Sakamoto, Y., Kurosaki, M., Umeyama, Y., Kamei, Y., Yoshimitsu, J., Fujii, Y., et al. (2021) · Liver Cancer · doi:10.1159/000514420 · Cited by 111
Zhang, Y., & Ertl, H. C. J. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00032 · Cited by 108
Jiang, K., Li, J., Zhang, J., Wang, L., Zhang, Q., Ge, J., Guo, Y., Wang, B., Huang, Y., Yang, T., et al. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105818 · Cited by 107
Xie, C., Duffy, A. G., Brar, G. S., Fioravanti, S., Mabry‐Hrones, D., Walker, M., Bonilla, C. M., Wood, B. J., Citrin, D. E., Ramirez, E. M. G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3624 · Cited by 107
Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer
Kverneland, A. H., Pedersen, M., Westergaard, M. C. W., Nielsen, M., Borch, T. H., Olsen, L. R., Aasbjerg, G. N., Santegoets, S. J. A. M., van der Burg, S. H., Milne, K., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27604 · Cited by 107
Mullinax, J. E., Hall, M. S., Prabhakaran, S., Weber, J. S., Khushalani, N. I., Eroglu, Z., Brohl, A. S., Markowitz, J., Royster, E. B., Richards, A. D., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00044 · Cited by 106
Orecchioni, S., Talarico, G., Labanca, V., Calleri, A., Mancuso, P., & Bertolini, F. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0076-z · Cited by 105
Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer
Pu, D., Yin, L., Huang, L., Qin, C., Zhou, Y., Wu, Q., Li, Y., Zhou, Q., & Li, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.637504 · Cited by 105
Maude, S. L., Hucks, G., Seif, A. E., Talekar, M. K., Teachey, D. T., Baniewicz, D., Callahan, C. A., Gonzalez, V. E., Nazimuddin, F., Gupta, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.103 · Cited by 102
Mukherji, S. K. (2009) · American Journal of Neuroradiology · doi:10.3174/ajnr.a1987 · Cited by 99
Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma
Huang, P.-Y., Guo, S.-S., Zhang, Y., Lu, J.-B., Chen, Q.-Y., Tang, L.-Q., Zhang, L., Liu, L.-T., Zhang, L., & Mai, H.-Q. (2016) · Oncotarget · doi:10.18632/oncotarget.7421 · Cited by 96
Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade
Nair, S., Mazzoccoli, L., Jash, A., Govero, J., Bais, S. S., Hu, T., Fontes-Garfias, C. R., Shan, C., Okada, H., Shresta, S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.144619 · Cited by 96
Adusumilli, P. S., Zauderer, M. G., Rusch, V. W., O'Cearbhaill, R. E., Zhu, A., Ngai, D. A., McGee, E., Chintala, N. K., Messinger, J., Cheema, W., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2511 · Cited by 93
Dudzinski, S. O., Cameron, B. D., Wang, J., Rathmell, J. C., Giorgio, T. D., & Kirschner, A. N. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0704-z · Cited by 93
Lee, E. K., Xiong, N., Cheng, S., Barry, W. T., Penson, R. T., Konstantinopoulos, P. A., Hoffman, M. A., Horowitz, N. S., Dizon, D. S., Stover, E. H., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.07.028 · Cited by 93
Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models
Chen, C., Wang, P.-Y., Hutzen, B. J., Sprague, L., Swain, H. M., Love, J., Stanek, J. R., Boon, L., Conner, J., & Cripe, T. P. (2017) · Scientific Reports · doi:10.1038/s41598-017-02503-8 · Cited by 92
PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition
Cretella, D., Digiacomo, G., Giovannetti, E., & Cavazzoni, A. (2019) · Cancers · doi:10.3390/cancers11091318 · Cited by 92
Cohen, E. E. W., Harrington, K. J., Tourneau, C. L., Dinis, J., Licitra, L. F., Ahn, M.-J., Soria, A., Machiels, J.-P., Mach, N., Mehra, R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx440.040 · Cited by 91
Saha, D., Martuza, R. L., & Rabkin, S. D. (2018) · Immunotherapy · doi:10.2217/imt-2018-0009 · Cited by 89
Yang, Q., Shi, G., Chen, X., Lin, Y., Cheng, L., Jiang, Q., Yan, X., Jiang, M., Li, Y., Zhang, H., et al. (2020) · Theranostics · doi:10.7150/thno.45391 · Cited by 89
Kanaya, N., Kuroda, S., Kakiuchi, Y., Kumon, K., Tsumura, T., Hashimoto, M., Morihiro, T., Kubota, T., Aoyama, K., Kikuchi, S., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.003 · Cited by 88
nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors
Soliman, H. H. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s122974 · Cited by 87
Cited by
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells
Garg, P., Malhotra, J., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024) · Cancers · doi:10.3390/cancers16132478 · Cited by 339
“Combining EMT inhibitors with immunotherapies, like immune checkpoint inhibitors, can bolster the immune system’s ability to fight cancer [32,53,61,77].”
BackgroundA comprehensive review of immune checkpoint inhibitors for cancer treatment
Arafat Hossain, M. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 178
Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
Roy, D., Gilmour, C., Patnaik, S., & Wang, L. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1264327 · Cited by 53
Wu, X.-H., Wang, J.-Q., Wang, M.-D., Xiao, T., Wang, Y., Niu, J.-Y., Wang, L., Hou, D.-Y., Fu, B., Liu, Z., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122550 · Cited by 9
Metadata
- Authors
- Vafaei, S., Zekiy, A. O., Khanamir, R. A., Zaman, B. A., Ghayourvahdat, A., Azimizonuzi, H., & Zamani, M.
- Venue
- Cancer Cell International
- Published
- 2022-01-03
- Volume
- 22
- Issue
- 1
- Pages
- 2-2
- ISSN
- 1475-2867 (ISSN-L)
- OpenAlex
- W4205315499
- Cited by
- 270
- References
- 302
- FWCI
- 20.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.